Drug Class Detail

Drug Class KIT Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Motesanib AMG 706 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 RET Inhibitor 36 VEGFR Inhibitor (Pan) 29 Motesanib (AMG 706) is a multi-kinase inhibitor, which inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), Kit, and Ret receptors, thereby inhibiting angiogenesis and inducing tumor regression (PMID: 16951187, PMID: 21422803).
Amuvatinib MP470|HPK56 AXL Inhibitor 24 FLT3 Inhibitor 48 KIT Inhibitor 48 MET Inhibitor 50 PDGFR-alpha Inhibitor 7 RET Inhibitor 36 Amuvatinib (MP470) is a multi-kinase inhibitor, with activity against KIT, MET, AXL, RET, FLT3, and PDGFR-alpha, that also inhibits Rad51 induction, which may enhance the efficacy of chemotherapeutic agents (PMID: 17325667, PMID: 21903282, PMID: 20563581).
RXDX-105 AC013773|CEP-32496 ABL Inhibitor (pan) 8 ABL1 Inhibitor 4 BCR-ABL Inhibitor 23 BRAF Inhibitor 18 CRAF Inhibitor 10 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RET Inhibitor 36 VEGFR2 Inhibitor 34 RXDX-105 (CEP-32496) inhibits wild-type BRAF, BRAF V600E, c-RAF, ABL1 (and BCR-ABL), c-KIT, RET, PDGFR beta, and VEGFR2, potentially resulting in decreased tumor growth (PMID: 22319199).
Pazopanib Votrient GW-786034 FGFR1 Inhibitor 21 FGFR2 Inhibitor 15 FGFR3 Inhibitor 12 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 VEGFR Inhibitor (Pan) 29 Votrient (pazopanib) inhibits VEGFR-1, -2 and -3, KIT, and PDGFR, and FGFR1, 2, and 3, leading to decreased tumor angiogenesis and growth (PMID: 17620431, PMID: 23786770). Votrient (pazopanib) is approved for renal cell carcinoma and soft tissue sarcoma (FDA.gov).
Pexidartinib PLX3397 CSF1R Inhibitor 22 FLT3 Inhibitor 48 KIT Inhibitor 48 Pexidartinib (PLX3397) inhibits multiple receptor tyrosine kinases, including KIT, CSF1R, FLT3, and FLT3/ITD, which may inhibit growth in cancer cells (PMID: 22294205, PMID: 25993548, PMID: 25847190).
Derazantinib ARQ 087 FGFR1 Inhibitor 21 FGFR2 Inhibitor 15 KIT Inhibitor 48 Derazantinib (ARQ 087) is an ATP-competitive multi-kinase inhibitor with activity against Fgfr 1/2, FGFR fusions, Arg, Lck, and Kit, which prevents cell proliferation and angiogenesis (PMID: 27627808).
SU11652 FGFR1 Inhibitor 21 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 VEGFR2 Inhibitor 34 SU11652 is an inhibitor of multiple tyrosine kinase receptors including Pdgfr-beta, Kdr (Vegfr2), Fgfr1, and Kit, which blocks pathway activation, promotes cell cycle arrest, and induces apoptosis of tumor cells (PMID: 12091352, PMID: 23216927).
Axitinib Inlyta AG-013736 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 VEGFR Inhibitor (Pan) 29 Inlyta (axitinib) inhibits the VEGFRs, PDGFR, and KIT, potentially resulting in decreased angiogenesis and reduced tumor growth (PMID: 16027439, PMID: 25709499). Inlyta (axitinib) is approved for renal cell carcinoma (FDA.gov).
Lenvatinib Lenvima E7080 FGFR Inhibitor (Pan) 17 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 RET Inhibitor 36 VEGFR Inhibitor (Pan) 29 Lenvima (lenvatinib) inhibits VEGFR, FGFR, PDGFR, KIT, and RET, and suppresses cell proliferation and angiogenesis (PMID: 21781317, PMID: 25295214, PMID: 17943726). Lenvima (lenvatinib) is FDA approved for use in patients with radioactive iodine-refractory differentiated thyroid cancer, unresectable hepatocellular carcinoma, and in combination with Afinitor (everolimus) for renal cell carcinoma (FDA.gov).
Vatalanib CGP-79787|PTK787|ZK 222584 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 VEGFR Inhibitor (Pan) 29 Vatalanib inhibits VEGFR1-3, PDGFRs, and KIT, potentially resulting in decreased tumor angiogenesis and growth (PMID: 23700288, PMID: 12124335).
Masitinib AB1010 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 Masitinib (AB1010) inhibits several receptor tyrosine kinases including c-KIT, PDGFR, and LYN, which may result in inhibition of cell proliferation (PMID: 19789626).
AG1295 AG-1295 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 AG1295 inhibits the tyrosine kinase activity of PDGFRA, PDGFRB, KIT, and FLT3, which may inhibit growth and promote apoptosis in cancer cells (PMID: 11468194, PMID: 7954456).
XL999 FGFR1 Inhibitor 21 FGFR3 Inhibitor 12 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RET Inhibitor 36 SRC Inhibitor 26 VEGFR2 Inhibitor 34 XL999 inhibits multiple tyrosine kinases including VEGFR2/KDR, FGFR1/3, PDGFR-beta, FLT3, RET, KIT, and SRC, which can result in anti-tumor activity (J Clin Oncol, 25:18s, 2007 (suppl;abstr 3591), PMID: 19581523).
MGCD516 Sitravatinib AXL Inhibitor 24 DDR1 Inhibitor 8 DDR2 inhibitor 7 KIT Inhibitor 48 MET Inhibitor 50 RET Inhibitor 36 Trk Receptor Inhibitor (Pan) 21 VEGFR Inhibitor (Pan) 29 MGCD516 (Sitravatinib) inhibits several receptor tyrosine kinases including AXL, MET, KIT, VEGFR1-3, RET family members, TRK family members, DDR, and Eph family members, resulting in abrogation of downstream signaling and decreased cell proliferation in tumors overexpressing the target proteins (PMID: 26675259).
Chiauranib CS2164 Aurkb Inhibitors 17 CSF1R Inhibitor 22 KIT Inhibitor 48 PDGFR-alpha Inhibitor 7 VEGFR Inhibitor (Pan) 29 Chiauranib (CS2164) is a multi-kinase inhibitor that inhibits AURKB, CSF-1R, VEGFRs, KIT, and PDGFRA, resulting in decreased tumor growth and angiogenesis (PMID: 28004478).
Sorafenib Nexavar BAY 43-9006 CSF1R Inhibitor 22 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RAF Inhibitor (Pan) 17 RET Inhibitor 36 VEGFR2 Inhibitor 34 Nexavar (sorafenib) is a multikinase inhibitor with activity against several kinases, including RAF kinases, VEGFR2, VEGFR3, PDGFR-beta, KIT, FLT3, RET, and CSF1R, potentially resulting in decreased tumor growth (PMID: 18445656, PMID: 15466206, PMID: 21517818). Nexavar (sorafenib) is approved for metastatic differentiated thyroid carcinoma, hepatocellular carcinoma, and renal cell carcinoma (FDA.gov).
Dasatinib Sprycel BMS-354825 ABL Inhibitor (pan) 8 BCR-ABL Inhibitor 23 BTK inhibitor 20 CSF1R Inhibitor 22 DDR1 Inhibitor 8 DDR2 inhibitor 7 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 SRC Inhibitor 26 TNK2 Inhibitor 6 Sprycel (dasatinib) is an inhibitor of the SRC-family of protein kinases, BCR-ABL, and ABL, and has additional activity against other kinases including KIT, DDR1/2, PDGFRA/B, and EPHA2, which prevents cell growth (PMID: 25709401, PMID: 25284748, PMID: 18797457). Sprycel (dasatinib) is FDA approved for both Philadelphia chromosome positive adult and pediatric chronic myelogenous leukemia and adult acute lymphoblastic leukemia (FDA.gov).
Cabozantinib Cometriq Cabometyx|Cabozantinib-s-malate|XL184 AXL Inhibitor 24 FLT3 Inhibitor 48 KIT Inhibitor 48 MET Inhibitor 50 RET Inhibitor 36 ROS1 Inhibitor 14 VEGFR2 Inhibitor 34 Cometriq (Cabometyx, cabozantinib) inhibits several receptor tyrosine kinases, including VEGFR2, FLT3, AXL, MET, RET, ROS1 fusions, and c-KIT (PMID: 27370605, PMID: 21926191). Cometriq (cabozantinib) is FDA approved for medullary thyroid cancer and Cabometyx (cabozantinib) is FDA approved for advanced renal cell carcinoma and in sorafenib previously treated hepatocellular carcinoma (FDA.gov).
OSI-930 KIT Inhibitor 48 VEGFR2 Inhibitor 34 OSI-930 binds and inhibits Kdr (Vegfr2) and Kit reducing cell proliferation and tumor growth (PMID: 16424037).
Sunitinib Sutent SU011248 CSF1R Inhibitor 22 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 RET Inhibitor 36 VEGFR2 Inhibitor 34 Sutent (sunitinib) inhibits KDR (VEGFR2), PDGFR, c-KIT, FLT3, RET, and CSF1R, thereby inhibiting angiogenesis and cell proliferation (NCI Drug Dictionary; PMID: 25085632). Sutent (sunitinib) is approved for neuroendocrine tumors of the pancreas, advanced renal cell carcinoma, and GIST (FDA.gov).
SU14813 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 VEGFR Inhibitor (Pan) 29 SU14813 is a multi-kinase inhibitor with activity against VEGFR1-3, PDGFRA, PDGFRB, KIT, and FLT3, which potentially results in decreased tumor angiogenesis and growth (PMID: 16891463, PMID: 20605934).
Midostaurin Rydapt PKC412|CGP 41251 CSF1R Inhibitor 22 FLT3 Inhibitor 48 KIT Inhibitor 48 PKC alpha Inhibitor 6 PKC beta Inhibitor 6 PKC Inhibitor (Pan) 9 VEGFR2 Inhibitor 34 Rydapt (midostaurin) is a multi-kinase inhibitor with activity against FLT3, KIT, PDGFRB, KDR (VEGFR2) and PKC, with higher selectivity for conventional PKC isoforms, which induces cell cycle arrest and apoptosis (PMID: 12124173, PMID: 23127174, PMID: 15914319). Rydapt (midostaurin) is FDA approved for FLT3-mutant AML in combination with chemotherapy, and is approved for use in aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia as a single therapy (FDA.gov).
Linifanib ABT-869|AL-39324 CSF1R Inhibitor 22 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 VEGFR Inhibitor (Pan) 29 Linifanib (ABT-869) is a receptor tyrosine kinase inhibitor with specificity against FLT1 (VEGFR1), CSF-1R, KDR (VEGFR2), FLT3, and KIT, which may result in inhibition of cell proliferation and tumor growth, and tumor regression (PMID: 16648571).
Cediranib AZD-2171|Recentin KIT Inhibitor 48 VEGFR1 Inhibitor 4 VEGFR2 Inhibitor 34 VEGFR3 Inhibitor 5 Cediranib (AZD-2171) is an ATP-competitive inhibitor of all three vascular endothelial growth factor receptors (FLT1, KDR, and FLT4) and KIT, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth (PMID: 15899831, PMID: 24714778).
Orantinib SU6668|TSU-68 FGFR1 Inhibitor 21 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 VEGFR2 Inhibitor 34 Orantinib (SU6668) inhibits several receptor tyrosine kinases KDR, PDGFRB, FGFR1, and KIT, thereby resulting in tumor growth inhibition (PMID: 17367541, PMID: 16144927).
Nilotinib Tasigna AMN-107 ABL Inhibitor (pan) 8 BCR-ABL Inhibitor 23 CSF1R Inhibitor 22 DDR1 Inhibitor 8 DDR2 inhibitor 7 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 Tasigna (nilotinib) inhibits several tyrosine kinases including BCR-ABL, PDGFR, KIT, DDR and CSF-1R, potentially resulting in reduced tumor cell proliferation (PMID: 21419934, PMID: 25284748). Tasigna (nilotinib) is FDA approved for use in patients with Ph+ chronic myeloid leukemia (FDA.gov).
Famitinib SHR1020 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RET Inhibitor 36 VEGFR2 Inhibitor 34 VEGFR3 Inhibitor 5 Famitinib is an analog of Sutent (sunitinib), a receptor tyrosine kinase (RTK) inhibitor, which inhibits receptor tyrosine kinases including c-Kit, VEGFR2/3, PDGFR-beta, RET, and FLT3 to reduce cell proliferation and tumor growth (PMID: 23126373).
DCC-2618 KIT Inhibitor 48 PDGFR-alpha Inhibitor 7 DCC-2618 is a dual inhibitor of KIT and PDGFRa, resulting in growth inhibition and anti-tumor effects (PMID: 29439183).
Dovitinib TKI258|CHIR-258 CSF1R Inhibitor 22 FGFR Inhibitor (Pan) 17 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 VEGFR Inhibitor (Pan) 29 Dovitinib (TKI258) targets multiple receptor tyrosine kinases including Flt3, c-Kit, CSF1R, FGFR 1-4, VEGFR 1-3, and PDGFR alpha and beta, potentially resulting in decreased tumor growth (PMID: 15598814, PMID: 25219510, PMID: 23658459, PMID: 16033847).
Avapritinib BLU-285 KIT Inhibitor 48 PDGFR-alpha Inhibitor 7 Avapritinib (BLU-285) is a selective inhibitor of PDGFRA D842V and KIT exon 17 mutants, including KIT D816V, potentially resulting in decreased tumor growth (AACR; 2015. Abstract nr 791).
Flumatinib HH-GV678 BCR-ABL Inhibitor 23 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 Flumatinib inhibits KIT, PDGFR, and BCR-ABL, potentially resulting in decreased tumor cell proliferation (NCI Drug Dictionary).
FF-10101 FF-10101-01 CSF1R Inhibitor 22 FLT3 Inhibitor 48 KIT Inhibitor 48 FF-10101 is a second generation and irreversible inhibitor of Flt3, including the internal tandem duplication (FLT3-ITD) and known resistance mutations (D835Y, Y842C, Y842H, or F691L) and also inhibits Kit and Csf1r (Fms) (PMID: 29187377)
Apatinib Rivoceranib YN968D1 KIT Inhibitor 48 RET Inhibitor 36 SRC Inhibitor 26 VEGFR2 Inhibitor 34 Apatinib (YN968D1) is an inhibitor of receptor tyrosine kinases, including KDR (VEGFR2), RET, c-KIT, Src, and PDGFRa, which may result in reduced cell proliferation and inhibition of tumor growth (PMID: 21443688).
GTP-14564 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 GTP-14564 is a selective inhibitor of FLT3, c-Fms, c-Kit, and PDGFR-beta, which may result in reduced downstream signaling and subsequent reductions in cell proliferation and tumor growth (PMID: 12815052).
Quizartinib AC220 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-alpha Inhibitor 7 RET Inhibitor 36 Quizartinib (AC220) targets both wild-type and mutant FLT3 containing activating internal tandem duplications, as well as PDGFRA, RET, and KIT, which may induce apoptosis and inhibit tumor growth (PMID: 19654408, PMID: 23497317).
PLX9486 KIT Inhibitor 48 PLX9486 is a Kit inhibitor with selective activity against primary (exon 9 and 11) and secondary (exon 17 and 18) Kit mutations, which may lead to growth inhibition in tumor cells expressing mutant c-Kit (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 11509-11509).
Telatinib BAY 57-9352 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 VEGFR2 Inhibitor 34 VEGFR3 Inhibitor 5 BAY 57-9352 (Telatinib) inhibits VEGFR2, VEGFR3, PDGFR-beta, and KIT, which may result in decreased proliferation and angiogenesis in tumors expressing these factors (NCI Drug Dictionary).
Regorafenib Stivarga BAY 73-4506 BRAF Inhibitor 18 CRAF Inhibitor 10 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 RET Inhibitor 36 VEGFR Inhibitor (Pan) 29 VEGFR2 Inhibitor 34 Stivarga (regorafenib) is an inhibitor of several kinases including VEGFR, RET, KIT, PDGFR and RAF, thereby inhibiting tumor angiogenesis and tumor cell proliferation (PMID: 24756792). Stivarga (regorafenib) is FDA approved for colorectal cancer, hepatocellular carcinoma, and GIST (FDA.gov).
EBI-907 BRAF Inhibitor 18 FGFR1 Inhibitor 21 FGFR2 Inhibitor 15 FGFR3 Inhibitor 12 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RET Inhibitor 36 EBI-907 is a multi-kinase inhibitor that inhibits BRAF V600E, FGFR1-3, RET, KIT, and PDGFRb, which results in tumor growth inhibition (PMID: 26810733).
Tandutinib MLN518|CT53518 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 Tandutinib (CT53518) is a tyrosine kinase inhibitor of FLT3, KIT, and PDGFRbeta, which inhibits cell proliferation and induces apoptosis (PMID: 12166950, PMID: 12124172).
AGL2043 AGL-2043 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 AGL2043 inhibits the tyrosine kinase activity of PDGFRA, PDGFRB, KIT, and FLT3, which may inhibit growth and promote apoptosis in cancer (PMID: 12670652).
Ponatinib Iclusig AP24534 BCR-ABL Inhibitor 23 DDR1 Inhibitor 8 DDR2 inhibitor 7 FGFR Inhibitor (Pan) 17 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-alpha Inhibitor 7 RET Inhibitor 36 SRC Inhibitor 26 VEGFR Inhibitor (Pan) 29 Iclusig (ponatinib) inhibits the Bcr-Abl fusion, and other tyrosine kinases, such as RET, DDR, VEGFR, FGFR, KIT, and FLT3 (PMID: 23526464, PMID: 25284748, PMID: 19878872). Iclusig (ponatinib) is FDA approved for chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph positive ALL) as well as ABL1 T315I CML and ABL1 T315I Ph positive ALL (FDA.gov).
Debio 0617B ABL Inhibitor (pan) 8 CSF1R Inhibitor 22 FLT3 Inhibitor 48 JAK Inhibitor (Pan) 8 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 SRC Inhibitor 26 VEGFR Inhibitor (Pan) 29 Debio 0617B is a multi-kinase inhibitor of SRC, JAK, and ABL, the class III kinases, CSF1R, FLT3, KIT, and PDGFR, and the class V kinases, VEGFR 1/2/3, which may result in inhibition of Stat3 and Stat5 signaling, leading to inhibition of tumor cell growth and metastasis (PMID: 27439479).
Imatinib mesylate Gleevec CGP-57148B|STI571 ABL Inhibitor (pan) 8 BCR-ABL Inhibitor 23 CSF1R Inhibitor 22 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 Gleevec (imatinib mesylate) is a multi-target inhibitor of c-Kit, Pdgfr, and Bcr-Abl (NCI Drug Dictionary). Gleevec (imatinib mesylate) is FDA approved for c-KIT positive GIST and dermatofibrosarcoma protuberans, Philadelphia chromosome positive chronic myeloid leukemia, and FIP1L1-PDGFRA positive chronic eosinophilic leukemia (FDA.gov).
CDX-0158 KTN0158 KIT Inhibitor 48 CDX-0158 (KTN0158) is a humanized anti-cKIT antibody that inhibits KIT signaling, resulting in inhibition of cell proliferation (Mol Cancer Ther December 2015 14; C167 ).
AG1296 AG-1296 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 AG1296 is a tyrphostin which binds and inhibits PDGFR and c-KIT which may reduce proliferation and tumor growth (PMID: 7954456, PMID: 15150607).
AKN-028 BVT-II|AKN028 FLT3 Inhibitor 48 KIT Inhibitor 48 AKN-028 inhibits wild-type and mutant forms of FLT3 and KIT, potentially resulting in decreased tumor cell proliferation (PMID: 22864397).
BPR1J373 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 RET Inhibitor 36 SRC Inhibitor 26 VEGFR Inhibitor (Pan) 29 BPR1J373 is a derivative of 5-phenylthiazol-2-ylamine-pyriminide that inhibits multiple tyrosine kinases including KIT, FLT3, VEGFR1, 2, 3, PDGFR-alpha, PDGFR-beta, RET, and SRC, and may result in anti-tumor activity (PMID: 27512117).
Molecular Profile Protein Effect Treatment Approaches
KIT D572A gain of function - predicted KIT Inhibitor
KIT V825A unknown KIT Inhibitor
KIT V559A gain of function KIT Inhibitor
KIT M552_Y553del gain of function - predicted KIT Inhibitor
KIT K550_V559del gain of function - predicted KIT Inhibitor
KIT W557del gain of function - predicted KIT Inhibitor
KIT N564_L576del gain of function - predicted KIT Inhibitor
KIT V559del gain of function KIT Inhibitor
KIT P551_V555delinsTL gain of function - predicted KIT Inhibitor
KIT D816G gain of function KIT Inhibitor Avapritinib
KIT D820H unknown KIT Inhibitor
KIT M552_D572del gain of function - predicted KIT Inhibitor
KIT K558_V560del gain of function - predicted KIT Inhibitor
KIT T417_D419delinsRA gain of function - predicted KIT Inhibitor
KIT V559_T574del gain of function - predicted KIT Inhibitor
KIT W557S unknown KIT Inhibitor
KIT K558_Y570delinsNP gain of function - predicted KIT Inhibitor
KIT P551_V555del gain of function KIT Inhibitor
KIT Q556_V559delinsH gain of function - predicted KIT Inhibitor
KIT K558_E562del gain of function - predicted KIT Inhibitor
KIT A502_Y503dup gain of function KIT Inhibitor
KIT K550_W557del gain of function - predicted KIT Inhibitor
KIT V560G gain of function KIT Inhibitor
KIT N564_Y578del gain of function - predicted KIT Inhibitor
KIT W557_V559del gain of function - predicted KIT Inhibitor
KIT Y553_E561delinsLK gain of function - predicted KIT Inhibitor
KIT S476I gain of function KIT Inhibitor
KIT T417_Y418delinsH gain of function - predicted KIT Inhibitor
KIT V559_E561del gain of function - predicted KIT Inhibitor
KIT W557_K558delinsC gain of function - predicted KIT Inhibitor
KIT K509I gain of function KIT Inhibitor
KIT V559D gain of function KIT Inhibitor
KIT Y823N unknown KIT Inhibitor
KIT W557_K558del gain of function KIT Inhibitor
KIT D820G unknown KIT Inhibitor
KIT K550_E554del gain of function - predicted KIT Inhibitor
KIT W557_K558delinsF gain of function - predicted KIT Inhibitor
KIT V559I gain of function KIT Inhibitor
KIT V569_L576del gain of function - predicted KIT Inhibitor
KIT P551_M552delinsL gain of function - predicted KIT Inhibitor
KIT V555_E562del gain of function - predicted KIT Inhibitor
KIT I563_L576del gain of function - predicted KIT Inhibitor
KIT M552_V559del gain of function - predicted KIT Inhibitor
KIT D816F gain of function KIT Inhibitor Avapritinib
KIT V559_V560delinsS gain of function - predicted KIT Inhibitor
KIT P551_Q556del gain of function - predicted KIT Inhibitor
KIT C443Y gain of function - predicted KIT Inhibitor
KIT V559_V560del gain of function KIT Inhibitor
KIT E490K unknown KIT Inhibitor
KIT D60N unknown KIT Inhibitor
KIT S501_A502insSAY gain of function - predicted KIT Inhibitor
KIT N567_P573del gain of function - predicted KIT Inhibitor
KIT N822Y gain of function - predicted KIT Inhibitor
KIT K558_Y570delinsN gain of function - predicted KIT Inhibitor
KIT amp no effect KIT Inhibitor
KIT N822I gain of function KIT Inhibitor
KIT Y553_Q556del gain of function KIT Inhibitor
KIT V530I gain of function KIT Inhibitor
KIT R634W gain of function KIT Inhibitor
KIT M552_V559delinsI gain of function - predicted KIT Inhibitor
KIT M552_K558del gain of function - predicted KIT Inhibitor
KIT V555_I571del gain of function - predicted KIT Inhibitor
KIT Y570_L576del gain of function - predicted KIT Inhibitor
KIT Y553N unknown KIT Inhibitor
KIT Q556_V559del gain of function - predicted KIT Inhibitor
KIT D816I gain of function KIT Inhibitor Avapritinib
KIT Y823D gain of function KIT Inhibitor
KIT N505I gain of function KIT Inhibitor
KIT V555_P573del gain of function - predicted KIT Inhibitor
KIT T670I gain of function KIT Inhibitor
KIT M552_E554del gain of function - predicted KIT Inhibitor
KIT V560E gain of function - predicted KIT Inhibitor
KIT exon 11 del gain of function KIT Inhibitor
KIT V556_V560del gain of function - predicted KIT Inhibitor
KIT K558delinsNP unknown KIT Inhibitor
KIT L576P gain of function KIT Inhibitor
KIT Q556_K558del gain of function - predicted KIT Inhibitor
KIT Q556_W557del gain of function - predicted KIT Inhibitor
KIT V560A gain of function - predicted KIT Inhibitor
KIT V560_L576del gain of function - predicted KIT Inhibitor
KIT W557_E561del gain of function - predicted KIT Inhibitor
KIT D820Y gain of function KIT Inhibitor
KIT V560_Y578del gain of function - predicted KIT Inhibitor
KIT K642E gain of function KIT Inhibitor
KIT D816E unknown KIT Inhibitor Avapritinib
KIT D816Y gain of function KIT Inhibitor Avapritinib
KIT T417_D419delinsY gain of function KIT Inhibitor
KIT W557R gain of function KIT Inhibitor
KIT K558_V559del gain of function - predicted KIT Inhibitor
KIT Q556_V560del gain of function - predicted KIT Inhibitor
KIT V555_V559del gain of function - predicted KIT Inhibitor
KIT D579del gain of function KIT Inhibitor
KIT V559K gain of function - predicted KIT Inhibitor
KIT K558_N564del gain of function - predicted KIT Inhibitor
KIT L576del gain of function - predicted KIT Inhibitor
KIT W557C unknown KIT Inhibitor
KIT V560del gain of function - predicted KIT Inhibitor
KIT Y418_D419delinsS gain of function - predicted KIT Inhibitor
KIT M552_E554delinsK gain of function - predicted KIT Inhibitor
KIT S501_A502dup gain of function - predicted KIT Inhibitor
KIT E554_D572delinsA gain of function - predicted KIT Inhibitor
KIT P577del gain of function - predicted KIT Inhibitor
KIT V555_V560del gain of function - predicted KIT Inhibitor
KIT P577_D579del gain of function - predicted KIT Inhibitor
KIT N655K gain of function - predicted KIT Inhibitor
KIT N822K gain of function KIT Inhibitor Avapritinib
KIT W557G gain of function - predicted KIT Inhibitor
KIT W557_V560del gain of function - predicted KIT Inhibitor
KIT V560D gain of function KIT Inhibitor
KIT D419del gain of function KIT Inhibitor
KIT P551_W557delinsL gain of function - predicted KIT Inhibitor
KIT V556_L576del gain of function - predicted KIT Inhibitor
KIT M552_Q556del gain of function - predicted KIT Inhibitor
KIT T417_D419delinsI gain of function - predicted KIT Inhibitor
KIT Y578C gain of function - predicted KIT Inhibitor
KIT V559G gain of function - predicted KIT Inhibitor
KIT W557_K558delinsE gain of function - predicted KIT Inhibitor
KIT D816N gain of function KIT Inhibitor Avapritinib
KIT M552_W557del gain of function - predicted KIT Inhibitor
KIT Y553_K558del gain of function - predicted KIT Inhibitor
KIT Y568_T574del gain of function - predicted KIT Inhibitor
KIT P551_E554del gain of function - predicted KIT Inhibitor
KIT D820V unknown KIT Inhibitor
KIT act mut gain of function KIT Inhibitor
KIT K558_G565delinsR gain of function - predicted KIT Inhibitor
KIT K558_D572del gain of function - predicted KIT Inhibitor
KIT V555_Q556del gain of function - predicted KIT Inhibitor
KIT V555_K558del gain of function - predicted KIT Inhibitor
KIT M552_V555del gain of function - predicted KIT Inhibitor
KIT S628N gain of function KIT Inhibitor
KIT Y553_W557del gain of function - predicted KIT Inhibitor
KIT E554_K558del gain of function - predicted KIT Inhibitor
KIT K550_K558del gain of function KIT Inhibitor
KIT A829P gain of function KIT Inhibitor
KIT Y418_D419delinsG gain of function - predicted KIT Inhibitor
KIT V559_G565del gain of function - predicted KIT Inhibitor
KIT K550_V555delinsI gain of function - predicted KIT Inhibitor
KIT K558_Y570delinsR gain of function - predicted KIT Inhibitor
KIT F522C gain of function - predicted KIT Inhibitor
KIT H697Y gain of function - predicted KIT Inhibitor
KIT I571_L576del gain of function - predicted KIT Inhibitor
KIT Y578_D579del gain of function - predicted KIT Inhibitor